Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Michael O'Riordan

November 20, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Conference News TCT 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

L.A. McKeown

October 09, 2019

News Daily News

PARTNER 2A at EACTS 2019: ‘The Message Is Exactly the Same’

Shelley Wood

October 08, 2019

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Todd Neale

September 29, 2019

Presentation TCT 2019

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Vinod Thourani

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

Shelley Wood

September 27, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Opinion Fellow Talk

What I Am Most Looking Forward to at TCT 2019

Mahesh V. Madhavan, MD

September 18, 2019

News Daily News

Aortic Stenosis Staging System Validated in Real-World, All-Comers Cohort

L.A. McKeown

February 14, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Vinod Thourani About PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

September 28, 2019

CME

Advertisement

Signal of Impaired Sapien XT Durability in Midterm Follow-up

TCTMD’s Top 10 Most Popular Stories for October 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

PARTNER 2A at EACTS 2019: ‘The Message Is Exactly the Same’

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

TCT 2019 Day Two: Transcatheter Valves, New and Old

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

What I Am Most Looking Forward to at TCT 2019

Aortic Stenosis Staging System Validated in Real-World, All-Comers Cohort

Dr. C. Michael Gibson Talks With Dr. Vinod Thourani About PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

New Clinical Data on TAVR use and Intermediate Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content